## **Original Article**

# Carotid Doppler Screening in Type 2 Diabetes Mellitus with Risk Factors

Nirav Sakariya<sup>1</sup>, Ravi Patel<sup>1</sup>, Vipul Srivastav<sup>2</sup>, Anokhi Shah<sup>3</sup>

Authors' affiliations: <sup>1</sup>Resident Doctor, <sup>2</sup>Professor & Head, Department of General Medicine, Surat Municipal Institute of Medical Education and Research, Surat, Gujarat; <sup>3</sup>Consultant Physician Correspondence: Dr. Vipul Srivastav, Email: vipul\_srivastav@yahoo.co.in

## ABSTRACT

**Objective:** To find out usefulness of screening by Carotid Doppler in type 2 Diabetes Mellitus with the four major modifiable risk factors i.e. smoking, hypertension, obesity and lipid profile by evaluating for the presence & extent of atherosclerotic carotid artery disease in asymptomatic Type 2 diabetics, by Carotid artery Doppler Ultrasonography.

**Methods**: This study, conducted in a tertiary care hospital of South Gujarat, enrolled 50 subjects who were known cases of type 2 DM with risk factors for accelerated atherosclerosis.

**Result:** The target population constituted 60% males and 40% females. There was a positive correlation of increase CIMT with duration of diabetes mellitus, HbA1c, LDL, TG and diabetic retinopathy.

**Conclusion:** The routine use of carotid Doppler screening of the type 2 DM with risk factors can be recommended in patient with longer duration of DM (>7 years), HbA1c (>7.5%), and altered lipid profile or patient having any end organ damage.

Key words: carotid intima-media thickness, type 2 diabetes mellitus

#### INTRODUCTION

India has been proposed as the diabetic capital of the world with the number of patients expected to rise from 40.9 to 101 million by 2030.<sup>1</sup>

As atherosclerosis is accelerated in patients of diabetes, the risk of coronary disorders and stroke in diabetic patients is three times that in individuals without this condition.<sup>2,3,4</sup> Stroke is one of the leading cause of morbidity and mortality in our country. Carotid artery stenosis, usually secondary to atherosclerosis, is one of the main causes of stroke. In-tima-media thickness (IMT) of common carotid artery is an excellent non-invasive measure of generalized atherosclerosis. It also serves as a surrogate marker of coronary artery disease (CAD)<sup>5</sup> and correlates strongly with future development of stroke and CAD.<sup>6</sup>

At present, carotid ultrasound is recommended in diabetic patients with cerebrovascular symptoms. Since the prevalence of diabetes is increasing constantly, it could be recommended for diabetic patients with at least one or more risk factors for accelerated atherosclerosis and for diabetic patients above 50 years of age.<sup>7,8</sup>

#### METHODS

The study was conducted amongst outdoor & indoor patients of the Surat municipal Institute of Medical education and research (SMIMER). OPD/Indoor patients at SMIMER, known case of type 2 diabetes mellitus with any of the following risk factors: Smoking, Hypertension, Obesity (BMI > 30kg/m<sup>2</sup>), High blood cholesterol (Total Cholesterol > 240 mg/dl) and willing to participate in the study were enrolled in the study. Patient of extremes of age (< 18 years or > 60 years), patient with other type of diabetes and patient with any evidence of cerebrovascular disease were excluded from the study.

Subjects were examined in the supine position, with the head turned 45° away from the side being scanned. The ultrasound system used was a VOLUSON S8 (GE Healthcare), equipped with a 5-10 MHz linear array transducer. The left and right common carotid arteries were examined in anterolateral, posterolateral, and mediolateral direction. The IMT of the carotid artery was measured as the distance from the leading edge of the first echogenic line, corresponding to the lumen-intimal interface, to that of the second echogenic line, corresponding to the corresponding to the collagen-contained upper layer of tunic adventitia<sup>12</sup>, as shown in figure below:



Figure 1: Intima media thickness

The measurement of IMT was made in a 1-cm segment proximal to the dilation of the carotid bulb and always in plaque-free segments. The artery was then searched for the presence of plaques. Plaque was defined as the presence of a focal lesion measuring at least twice the thickness of the IMT. The normal value of IMT in carotid vessels is <0.8 mm. While increased in IMT were divided in mild-0.8-1.2 mm, moderate- >1.2 - 1.6 mm and severe >1.6 mm. The raised IMT is a surrogate marker of accelerated atherosclerosis.

#### **OBSERVATIONS AND DISCUSSION**

This study, conducted in a tertiary care hospital of South Gujarat, enrolled 50 subjects who were known cases of type 2 DM with risk factors for accelerated atherosclerosis and the observation of study is as below:

The age range of the study subjects were 35 to 60 years, with a mean of 52  $\pm$  6.6 years. 32 of our patients (64%) were between the age ranges of 51 to 60 years. Similarly results of other variables according to stratification have been shown in Table-1. The mean IMT in >50 years age group was higher than  $\leq 50$  years age group, with a positive correlation and a statistically significant difference between the two groups. There were 30 male subjects in study and different parameter of blood investigation with mean value is stated in table number 2. There was no statistically difference in blood investigation according to gender. Correlation of various factors with carotid IMA is depicted in table 3. As the age progresses IMT was increased in diabetic patients which was also seen in study conducted by Bashir F et al13 and Taniguchi et al14; however, in another study conducted by Mujeeb-ur-Rehman et al15 no significant association was found between the two. This was due to accumulation of various stress factors over period of time. Though there was no difference in IMT between gender of subjects but Kong et al<sup>16</sup> found that CCA-IMT was closely associated with male sex, age and smoking.

The mean IMT was higher in subjects who had duration DM for >7 years, HbA1c > 7.5 %. Similar results were seen in a study conducted by Bashir F et al <sup>13</sup>, and Wagen knecht LE <sup>17</sup>; however, in other studies conducted by Mujeeb-ur-Rehman et al <sup>15</sup> and Taniguchi et al <sup>14</sup> no significant association was found between the two. However, when the duration of diabetes was reduced to 6 years or 5 years, the difference in the mean IMT was not statistically significant. Chronic hyperglycemia leads to change in vasculature leads to accelerated atherosclerosis and can be independent risk factor for it. <sup>14</sup>

The mean IMT was higher in subjects whose BMI >30 kg/m<sup>2</sup> but the difference was statistically not significant.

Taniguchi et al <sup>14</sup> found a strong association of age, duration of DM and raised non esterified free fatty acids while no correlation was seen with BMI and raised cholesterol or triglyceride levels. Ciccone M et al <sup>18</sup> found that CCA-IMT was correlated with smoking and body mass index. In contrast to our study, Ciccone et al <sup>18</sup> found that BMI is strongly and independently associated with the IMT of common carotid artery. Their results suggest that central fat accumulation may accelerate the development of earlier clinically silent stages of atherosclerosis, thus possibly explaining the higher prevalence of cardiovascular diseases in patients with abdominal obesity.

The mean IMT was higher in subjects who had Diabetic Retinopathy. The ARIC study found that the severity of retinopathy correlated positively with carotid artery intima media wall thickness.<sup>19</sup>

The mean IMT was higher in subjects who had altered lipid profile. Similar results were seen in a study conducted by Bashir F et al <sup>13</sup> and Wagen knecht LE<sup>17</sup>. Though it is well established that in non-diabetics, age, gender, total cholesterol and smoking are independent determinants of CCA-IMT.<sup>20</sup>

 
 Table 1: Demographic characteristics of the population

Parameters	Subjects (%)
Age (years)	
$\leq 50$	18 (36)
>50	32 (64)
Gender	
male	30 (60)
female	20 (40)
Duration (years)	
$\leq 5$	21 (42)
>5	29 (58)
Target organ damage	
Diabetic retinopathy	27 (54)
Diabetic neuropathy	17 (34)
Peripheral Arterial disease	10 (20)
Nephropathy	10 (20)
Cardiac complication	20 (40)
Risk factors	
Hypertension	27 (54)
Obesity	15 (30)
Smoking	15 (30)
Altered lipid profile	30 (60)
Number of risk factors	
$\leq 2$	43 (86)
>2	7 (14)
Stenosed vessel present	6 (12)

Table 2: Comparison	of Investigation	profile of study grou	n according to their gender
	or mit congation	prome or other, grou	p uccording to then genuer

Investigation	Mean Values ± SD		P value
	Male	Female	
FBS (mg/dl)	$162.53 \pm 56.68$	$143.25 \pm 34.17$	0.1794
PP2BS (mg/dl)	$243.1 \pm 74.38$	$233.7 \pm 53.38$	0.6285
HbA1c (%)	$7.54 \pm 0.84$	$7.25 \pm 0.71$	0.2103
TGs(mg/dl)	$200.13 \pm 90.98$	$152.35 \pm 45.92$	0.03
LDL (mg/dl)	$140.43 \pm 65.55$	$134.15 \pm 59.24$	0.7319

#### Table 3: Correlation of Risk Factors with Common Carotid Intimal- Medial Thickness

RightLeftAge $\leq 50 \text{ y} (n=18)$ $0.73 \pm 0.40$ $0.79 \pm 0.30$ $0.00012$ $>50 \text{ y} (n=32)$ $1.24 \pm 0.41$ $1.20 \pm 0.35$ $0.00012$ GenderMale(n=30) $1.15 \pm 0.45$ $1.12 \pm 0.40$ $0.1087$ Female(n=20) $0.93 \pm 0.49$ $0.95 \pm 0.35$ $0.1287$ Duration $\leq 7 \text{ y} (n=30)$ $0.91 \pm 0.43$ $0.95 \pm 0.37$ $0.00650$ $>7 \text{ y} (n=20)$ $1.28 \pm 0.48$ $1.21 \pm 0.36$ $0.0175$ Hypertension </th <th>Risk factors</th> <th>Common carotid art</th> <th>P value</th>	Risk factors	Common carotid art	P value	
Age		Right	Left	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Age			
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	≤50 y (n=18)	$0.73 \pm 0.40$	$0.79 \pm 0.30$	0.00012
Gender       Malc (n=30)       1.15 $\pm$ 0.45       1.12 $\pm$ 0.40       0.1087         Femalc (n=20)       0.93 $\pm$ 0.49       0.95 $\pm$ 0.35       0.1287         Duration $\leq$ 7 y (n=30)       0.91 $\pm$ 0.43       0.95 $\pm$ 0.37       0.00650         > 7 y (n=20)       1.28 $\pm$ 0.48       1.21 $\pm$ 0.36       0.0175         Hypertension             present       1.11 $\pm$ 0.52       1.08 $\pm$ 0.41       0.4241         absent       1.00 $\pm$ 0.43       1.02 $\pm$ 0.36       0.5882         BMI (kg/m <sup>2</sup> )             <30 (n=37)	>50 y (n=32)	$1.24 \pm 0.41$	$1.20 \pm 0.35$	0.00012
Male(n=30)       1.15 $\pm$ 0.45       1.12 $\pm$ 0.40       0.1087         Female(n=20)       0.93 $\pm$ 0.49       0.95 $\pm$ 0.35       0.1287         Duration	Gender			
Female(n=20) $0.93 \pm 0.49$ $0.95 \pm 0.35$ $0.1287$ Duration $\leq 7 \text{ y} (n=30)$ $0.91 \pm 0.43$ $0.95 \pm 0.37$ $0.00650$ >7 y (n=20) $1.28 \pm 0.48$ $1.21 \pm 0.36$ $0.0175$ Hypertension $m$ $m$ $n$ $n$ present $1.11 \pm 0.52$ $1.08 \pm 0.41$ $0.4241$ absent $1.00 \pm 0.43$ $1.02 \pm 0.36$ $0.5882$ BMI (kg/m²) $m$ $m$ $m$ $< 30 (n=37)$ $1.02 \pm 0.44$ $1.06 \pm 0.40$ $0.3690$ $\geq 30 (n=13)$ $1.16 \pm 0.58$ $1.03 \pm 0.34$ $0.8105$ HbA1C (%) $m$ $m$ $m$ $\leq 7.5\%$ (n=26) $0.86 \pm 0.43$ $0.94 \pm 0.38$ $0.00049$ $>7.5\%$ (n=24) $1.31 \pm 0.42$ $1.20 \pm 0.35$ $0.01550$ Retinopathy $m$ $m$ $m$ Normal fundus (n=23) $0.77 \pm 0.37$ $0.85 \pm 0.32$ $0.00002$ Retinopathy (n=27) $1.30 \pm 0.42$ $1.26 \pm 0.34$ $0.065$ Absent (n=35) $0.98 \pm 0.47$ $0.97 \pm 0.37$ $0.072$ Altered lipid profile $m$ $m$ $m$ TC > 240mg/dl (n=30) $1.00 \pm 0.50$ $1.02 \pm 0.40$ $0.2816$ TC $\leq 240mg/dl (n=30)$ $1.05 \pm 0.44$ $1.11 \pm 0.37$ $0.4261$ TG (mg/dl) $m$ $m$ $m$ $\leq 200 (n=24)$ $1.26 \pm 0.47$ $1.50.9$ $0.047$ HDL(mg/dl) $m$ $m$ $m$ $\leq 00 (n=24)$ $1.13 \pm 0.45$ $1.17 \pm 0.41$ $0.3047$ $< 00 (n=24)$ $1.13 \pm 0.45$ $1.17$	Male(n=30)	$1.15 \pm 0.45$	$1.12 \pm 0.40$	0.1087
Duration $\leq 7 \ y \ (n=30)$ 0.91 $\pm$ 0.430.95 $\pm$ 0.370.00650>7 y (n=20)1.28 $\pm$ 0.481.21 $\pm$ 0.360.0175Hypertensionpresent1.11 $\pm$ 0.521.08 $\pm$ 0.410.4241absent1.00 $\pm$ 0.431.02 $\pm$ 0.360.5882BMI (kg/m²)<30 (n=37)	Female(n=20)	$0.93 \pm 0.49$	$0.95 \pm 0.35$	0.1287
	Duration			
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	≤7 y (n=30)	$0.91 \pm 0.43$	$0.95 \pm 0.37$	0.00650
Hypertensionpresent $1.11 \pm 0.52$ $1.08 \pm 0.41$ $0.4241$ absent $1.00 \pm 0.43$ $1.02 \pm 0.36$ $0.5882$ BMI (kg/m <sup>2</sup> )<30 (n=37)	>7 y (n=20)	$1.28 \pm 0.48$	$1.21 \pm 0.36$	0.0175
present $1.11 \pm 0.52$ $1.08 \pm 0.41$ $0.4241$ absent $1.00 \pm 0.43$ $1.02 \pm 0.36$ $0.5882$ BMI (kg/m <sup>2</sup> )<30 (n=37)	Hypertension			
absent $1.00 \pm 0.43$ $1.02 \pm 0.36$ $0.5882$ BMI (kg/m²)	present	$1.11 \pm 0.52$	$1.08 \pm 0.41$	0.4241
BMI (kg/m <sup>2</sup> ) <30 (n=37) 1.02 ± 0.44 1.06 ± 0.40 0.3690 ≥30 (n=13) 1.16 ± 0.58 1.03 ± 0.34 0.8105 HbA1C (%) ≤7.5% (n=26) 0.86 ± 0.43 0.94 ± 0.38 0.00049 >7.5% (n=24) 1.31 ± 0.42 1.20 ± 0.35 0.01550 Retinopathy Normal fundus (n=23) 0.77 ± 0.37 0.85 ± 0.32 0.00002 Retinopathy (n=27) 1.30 ± 0.42 1.23 ± 0.35 0.00023 Smoking Present (n=15) 1.25 ± 0.45 1.26 ± 0.34 0.065 Absent (n=35) 0.98 ± 0.47 0.97 ± 0.37 0.072 Altered lipid profile TC > 240mg/dl (n=30) 1.00 ± 0.50 1.02 ± 0.40 0.2816 TC ≤ 240mg/dl (n=20) 1.15 ± 0.44 1.11 ± 0.37 0.4261 TG (mg/dl) ≤200 (n=26) 0.90 ± 0.41 0.96 ± 0.36 0.004 >200 (n=24) 1.26 ± 0.47 1.15 ± 0.39 0.047 HDL(mg/dl) ≤60 (n=24) 1.13 ± 0.45 1.17 ± 0.41 0.3047 >600 (n=26) 0.99 ± 0.50 0.95 ± 0.33 0.07122 HDL(mg/dl)	absent	$1.00 \pm 0.43$	$1.02 \pm 0.36$	0.5882
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	BMI $(kg/m^2)$			
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	<30 (n=37)	$1.02 \pm 0.44$	$1.06 \pm 0.40$	0.3690
HbA1C (%) $\leq 7.5\%$ (n=26) $0.86 \pm 0.43$ $0.94 \pm 0.38$ $0.00049$ $>7.5\%$ (n=24) $1.31 \pm 0.42$ $1.20 \pm 0.35$ $0.01550$ Retinopathy $Normal fundus (n=23)$ $0.77 \pm 0.37$ $0.85 \pm 0.32$ $0.00002$ Retinopathy (n=27) $1.30 \pm 0.42$ $1.23 \pm 0.35$ $0.00023$ Smoking $Present (n=15)$ $1.25 \pm 0.45$ $1.26 \pm 0.34$ $0.065$ Absent (n=35) $0.98 \pm 0.47$ $0.97 \pm 0.37$ $0.072$ Altered lipid profile $TC > 240mg/dl (n=30)$ $1.00 \pm 0.50$ $1.02 \pm 0.40$ $0.2816$ $TC \leq 240mg/dl (n=20)$ $1.15 \pm 0.44$ $1.11 \pm 0.37$ $0.4261$ $TG(mg/dl)$ $2200 (n=26)$ $0.90 \pm 0.41$ $0.96 \pm 0.36$ $0.004$ $>200 (n=24)$ $1.26 \pm 0.47$ $1.15 \pm 0.39$ $0.047$ HDL(mg/dl) $U(mg/dl)$ $U(mg/dl)$ $U(mg/dl)$ $U(mg/dl)$ $\leq 60 (n=24)$ $1.13 \pm 0.45$ $1.17 \pm 0.41$ $0.3047$ $>60 (n=26)$ $0.99 \pm 0.50$ $0.95 \pm 0.33$ $0.07122$	≥30 (n=13)	$1.16 \pm 0.58$	$1.03 \pm 0.34$	0.8105
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	HbA1C (%)			
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	≤7.5% (n=26)	$0.86 \pm 0.43$	$0.94 \pm 0.38$	0.00049
RetinopathyNormal fundus (n=23) $0.77 \pm 0.37$ $0.85 \pm 0.32$ $0.00002$ Retinopathy (n=27) $1.30 \pm 0.42$ $1.23 \pm 0.35$ $0.00023$ SmokingPresent (n=15) $1.25 \pm 0.45$ $1.26 \pm 0.34$ $0.065$ Absent (n=35) $0.98 \pm 0.47$ $0.97 \pm 0.37$ $0.072$ Altered lipid profileTC > 240mg/dl (n=30) $1.00 \pm 0.50$ $1.02 \pm 0.40$ $0.2816$ TC $\leq 240mg/dl$ (n=20) $1.15 \pm 0.44$ $1.11 \pm 0.37$ $0.4261$ TG(mg/dl) $\leq 200$ (n=26) $0.90 \pm 0.41$ $0.96 \pm 0.36$ $0.004$ $>200$ (n=24) $1.26 \pm 0.47$ $1.15 \pm 0.39$ $0.047$ HDL(mg/dl) $\leq 60$ (n=24) $1.13 \pm 0.45$ $1.17 \pm 0.41$ $0.3047$ $>60$ (n=26) $0.99 \pm 0.50$ $0.95 \pm 0.33$ $0.07122$	>7.5% (n=24)	$1.31 \pm 0.42$	$1.20 \pm 0.35$	0.01550
Normal fundus (n=23) $0.77 \pm 0.37$ $0.85 \pm 0.32$ $0.00002$ Retinopathy (n=27) $1.30 \pm 0.42$ $1.23 \pm 0.35$ $0.00023$ Smoking $Present (n=15)$ $1.25 \pm 0.45$ $1.26 \pm 0.34$ $0.065$ Absent (n=35) $0.98 \pm 0.47$ $0.97 \pm 0.37$ $0.072$ Altered lipid profile $TC > 240 mg/dl (n=30)$ $1.00 \pm 0.50$ $1.02 \pm 0.40$ $0.2816$ TC $\leq 240 mg/dl (n=20)$ $1.15 \pm 0.44$ $1.11 \pm 0.37$ $0.4261$ TG (mg/dl) $2200 (n=26)$ $0.90 \pm 0.41$ $0.96 \pm 0.36$ $0.004$ $\geq 200 (n=24)$ $1.26 \pm 0.47$ $1.15 \pm 0.39$ $0.047$ HDL(mg/dl) $\leq 60 (n=24)$ $1.13 \pm 0.45$ $1.17 \pm 0.41$ $0.3047$ $>60 (n=26)$ $0.99 \pm 0.50$ $0.95 \pm 0.33$ $0.07122$	Retinopathy			
Retinopathy (n=27) $1.30 \pm 0.42$ $1.23 \pm 0.35$ $0.00023$ SmokingPresent (n=15) $1.25 \pm 0.45$ $1.26 \pm 0.34$ $0.065$ Absent (n=35) $0.98 \pm 0.47$ $0.97 \pm 0.37$ $0.072$ Altered lipid profileTC > 240mg/dl (n=30) $1.00 \pm 0.50$ $1.02 \pm 0.40$ $0.2816$ TC $\leq 240$ mg/dl (n=20) $1.15 \pm 0.44$ $1.11 \pm 0.37$ $0.4261$ TG(mg/dl) $\leq 200$ (n=26) $0.90 \pm 0.41$ $0.96 \pm 0.36$ $0.004$ >200 (n=24) $1.26 \pm 0.47$ $1.15 \pm 0.39$ $0.047$ HDL(mg/dl) $\leq 60$ (n=24) $1.13 \pm 0.45$ $1.17 \pm 0.41$ $0.3047$ >60 (n=26) $0.99 \pm 0.50$ $0.95 \pm 0.33$ $0.07122$	Normal fundus (n=23)	$0.77 \pm 0.37$	$0.85 \pm 0.32$	0.00002
Smoking Present (n=15) $1.25 \pm 0.45$ $1.26 \pm 0.34$ $0.065$ Absent (n=35) $0.98 \pm 0.47$ $0.97 \pm 0.37$ $0.072$ Altered lipid profile $TC > 240 mg/dl (n=30)$ $1.00 \pm 0.50$ $1.02 \pm 0.40$ $0.2816$ TC $\le 240 mg/dl (n=20)$ $1.15 \pm 0.44$ $1.11 \pm 0.37$ $0.4261$ TG (mg/dl) $1.26 \pm 0.47$ $1.96 \pm 0.36$ $0.004$ $\ge 200 (n=26)$ $0.90 \pm 0.41$ $0.96 \pm 0.36$ $0.004$ $\ge 200 (n=24)$ $1.26 \pm 0.47$ $1.15 \pm 0.39$ $0.047$ HDL(mg/dl) $= 60 (n=24)$ $1.13 \pm 0.45$ $1.17 \pm 0.41$ $0.3047$ $\ge 60 (n=26)$ $0.99 \pm 0.50$ $0.95 \pm 0.33$ $0.07122$	Retinopathy $(n=27)$	$1.30 \pm 0.42$	$1.23 \pm 0.35$	0.00023
Present (n=15) $1.25 \pm 0.45$ $1.26 \pm 0.34$ $0.065$ Absent (n=35) $0.98 \pm 0.47$ $0.97 \pm 0.37$ $0.072$ Altered lipid profile $TC > 240 \text{mg/dl} (n=30)$ $1.00 \pm 0.50$ $1.02 \pm 0.40$ $0.2816$ TC $\le 240 \text{mg/dl} (n=20)$ $1.15 \pm 0.44$ $1.11 \pm 0.37$ $0.4261$ TG(mg/dl) $\le 200 \text{ (n=26)}$ $0.90 \pm 0.41$ $0.96 \pm 0.36$ $0.004$ $\ge 200 \text{ (n=24)}$ $1.26 \pm 0.47$ $1.15 \pm 0.39$ $0.047$ HDL(mg/dl) $\le 60 \text{ (n=24)}$ $1.13 \pm 0.45$ $1.17 \pm 0.41$ $0.3047$ $\ge 60 \text{ (n=26)}$ $0.99 \pm 0.50$ $0.95 \pm 0.33$ $0.07122$	Smoking			
Absent (n=35) $0.98 \pm 0.47$ $0.97 \pm 0.37$ $0.072$ Altered lipid profileTC > 240mg/dl (n=30) $1.00 \pm 0.50$ $1.02 \pm 0.40$ $0.2816$ TC $\leq 240$ mg/dl (n=20) $1.15 \pm 0.44$ $1.11 \pm 0.37$ $0.4261$ TG(mg/dl) $\leq 200 (n=26)$ $0.90 \pm 0.41$ $0.96 \pm 0.36$ $0.004$ >200 (n=24) $1.26 \pm 0.47$ $1.15 \pm 0.39$ $0.047$ HDL(mg/dl) $\leq 60 (n=24)$ $1.13 \pm 0.45$ $1.17 \pm 0.41$ $0.3047$ >60 (n=26) $0.99 \pm 0.50$ $0.95 \pm 0.33$ $0.07122$	Present (n=15)	$1.25 \pm 0.45$	$1.26 \pm 0.34$	0.065
Altered lipid profile $1.00 \pm 0.50$ $1.02 \pm 0.40$ $0.2816$ TC > 240mg/dl (n=30) $1.15 \pm 0.44$ $1.11 \pm 0.37$ $0.4261$ TG (mg/dl) $2200 (n=26)$ $0.90 \pm 0.41$ $0.96 \pm 0.36$ $0.004$ >200 (n=24) $1.26 \pm 0.47$ $1.15 \pm 0.39$ $0.047$ HDL(mg/dl) $260 (n=24)$ $1.13 \pm 0.45$ $1.17 \pm 0.41$ $0.3047$ >60 (n=26) $0.99 \pm 0.50$ $0.95 \pm 0.33$ $0.07122$	Absent (n=35)	$0.98 \pm 0.47$	$0.97 \pm 0.37$	0.072
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Altered lipid profile			
TC $\leq 240$ mg/dl (n=20)1.15 $\pm$ 0.441.11 $\pm$ 0.370.4261TG(mg/dl) $\leq 200$ (n=26)0.90 $\pm$ 0.410.96 $\pm$ 0.360.004>200 (n=24)1.26 $\pm$ 0.471.15 $\pm$ 0.390.047HDL(mg/dl) $\leq 60$ (n=24)1.13 $\pm$ 0.451.17 $\pm$ 0.410.3047>60 (n=26)0.99 $\pm$ 0.500.95 $\pm$ 0.330.07122	TC > 240 mg/dl (n=30)	$1.00 \pm 0.50$	$1.02 \pm 0.40$	0.2816
TG(mg/dl) $\leq 200 \text{ (n=26)}$ $0.90 \pm 0.41$ $0.96 \pm 0.36$ $0.004$ >200 (n=24) $1.26 \pm 0.47$ $1.15 \pm 0.39$ $0.047$ HDL(mg/dl) $\leq 60 \text{ (n=24)}$ $1.13 \pm 0.45$ $1.17 \pm 0.41$ $0.3047$ >60 (n=26) $0.99 \pm 0.50$ $0.95 \pm 0.33$ $0.07122$	$TC \le 240 mg/dl (n=20)$	$1.15 \pm 0.44$	$1.11 \pm 0.37$	0.4261
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	TG(mg/dl)			
>200 (n=24) $1.26 \pm 0.47$ $1.15 \pm 0.39$ $0.047$ HDL(mg/dl) $\leq 60 (n=24)$ $1.13 \pm 0.45$ $1.17 \pm 0.41$ $0.3047$ >60 (n=26) $0.99 \pm 0.50$ $0.95 \pm 0.33$ $0.07122$	≤200 (n=26)	$0.90 \pm 0.41$	$0.96 \pm 0.36$	0.004
HDL(mg/dl)1.13 $\pm$ 0.451.17 $\pm$ 0.410.3047>60 (n=26)0.99 $\pm$ 0.500.95 $\pm$ 0.330.07122	>200 (n=24)	$1.26 \pm 0.47$	1.15 ±0.39	0.047
$ \begin{array}{cccc} \leq 60 \ (n=24) & 1.13 \pm 0.45 & 1.17 \pm 0.41 & 0.3047 \\ > 60 \ (n=26) & 0.99 \pm 0.50 & 0.95 \pm 0.33 & 0.07122 \\ \end{array} $	HDL(mg/dl)			
>60 (n=26) $0.99 \pm 0.50$ $0.95 \pm 0.33$ $0.07122$	≤60 (n=24)	$1.13 \pm 0.45$	$1.17 \pm 0.41$	0.3047
	>60 (n=26)	$0.99 \pm 0.50$	$0.95 \pm 0.33$	0.07122
LJL(mg/ u)	LDL(mg/dl)			
$\leq 160 \text{ (n=23)}$ 0.86 ± 0.43 0.92 ± 0.37 0.004	≤160 (n=23)	$0.86 \pm 0.43$	$0.92 \pm 0.37$	0.004
>160 (n=27) 1.23 $\pm 0.45$ 1.17 $\pm 0.36$ 0.019	>160 (n=27)	$1.23 \pm 0.45$	$1.17 \pm 0.36$	0.019

Irrespective of well-known risk factors of atherosclerosis Geroulakos G et al <sup>21</sup> and Kanters SD<sup>22</sup> were unable to find any statistically significant correlation between CCA-IMT with age, gender, duration of DM, serum total cholesterol and triglyceride levels in patients with type 2 diabetes mellitus.

Naya et al <sup>23</sup> found smokers with high body mass index, high fasting serum insulin, or high systolic blood pressure to have larger CCA-IMT values than would be predicted by consideration solely of the individual risk factors but in our study, we could not find such an association. They also found that Diabetes mellitus status itself and even impaired glucose tolerance as compared to normal glucose tolerance is a strong predictor of CCA-IMT. It is probably explained by the fact that diabetes itself is of crucial importance for the development of atherosclerosis because of clustering of multiple interrelated metabolic disturbances that it over shadows the contribution of other risk factors. In our study also majority of patients had other risk factors in addition to diabetes mellitus.

### CONCLUSION

On the basis of our study, it can be recommended that Carotid Doppler scanning must be done on Diabetic patients, if - Duration of DM > 7 years, HbA1c > 7.5 %, LDL > 160 mg/dl and TG > 200 mg/dl, Diabetic Retinopathy, BMI > 30 Kg/m<sup>2</sup> and/or Hypertension

In conclusion, our data shows that CCA-IMT is directly associated with, duration of DM, LDL, TG, HbA1c and diabetic retinopathy. This study therefore suggests that the carotid intima-media thickness may be clinically useful in the monitoring of vascular changes in the management of type 2 diabetics. Considering the conflicting outcomes of different studies, it is suggested that further research is required in larger number of patients to find out the interrelationship and contribution of various risk factors of carotid atherosclerosis in diabetic patients. Our preliminary study paves way for further randomized studies including large number of patients from multiple centers with longer follow-up, which would assess the role of CIMT in predicting the development of various complications and how the various available treatment strategies could be incorporated to influence the outcome.

#### REFERENCES

- 1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care2004; 27:1047-53.
- Spijkerman AM, Henry RM, Dekker JM, Nijpels G,Kostense PJ, Kors JA, et al. Prevalence of macrovascular disease amongst type 2 diabetic patients detected by targeted screening and patients newly diagnosed in general practice: The Hoorn Screening Study. J Intern Med 2004; 256:429-36.
- Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–44.
- Weinberger J, Biscarra V, Weisberg MK, Jacobson JH. Factors contributing to stroke in patients with atherosclerotic disease of the great vessels: the role of diabetes. Stroke 1983; 14: 709– 12.
- Mukherjee SC, Basu AK, Bandyopadhyay R, Pal SK, Bandopadhyay D, Mandal SK, et al. Correlation oflipid profile and carotid artery plaque as detected by Doppler ultrasound in ischaemic stroke patients –A hospital-based study.J Indian Med Assoc 2006;104:325-6,330.
- Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128:262-9.
- American Heart Association. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group III. Risk assessment in persons with diabetes. Circulation 2002; 105: e144–e52.
- Strategies for care of the type 2 diabetic patient excluding care of complications. Recommendations of ANAES (National Agency for Health Accreditation and Evaluation March 2000). Diabetes Metab 2000; 26 (S5): 10–96.
- Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1985; 273: 1421–28.
- MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomized controlled trial. Lancet 2004; 363: 1491–502.

- American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus. DiabetesCare.2010; 33(1):62-69.
- Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002; 287: 2570–2581.
- Bashir F, Nageen A, Kidwai SS, Ara J. Carotid intima-media thickness and cardiometabolic risk factors in Pakistani type 2 diabetics. Saudi J Health Sci 2017;6:145-50.
- 14. Taniguchi A, Nakai Y, Fukushima M, Teramura S, Hayashi R, Hama K, et al. Ultrasonographically assessed carotid atherosclerosis in Japanese type 2 diabetic patients: Role of nonesterified fatty acids. Metabolism 2002; 51: 539-43.
- Mujeeb-ur-Rehman, A.B. and Manzar, Z. (2009) Association of Common Carotid Intimal Medial Thickness (CCA-IMT) with Risk Factors of Atherosclerosis in Patients with Type 2 Diabetes Mellitus. Journal of the Pakistan Medical Association, 59, 590-593.
- Kong C, Elatrozy T, Anyaoku V, Robinson S, Richmond W, Elkeles RS. Insulin resistance, cardiovascular risk factors and ultrasonically measured early arterial disease in normotensive Type 2 diabetic subjects. Diabetes Metab Res Rev 2000; 16: 448-53.
- Wagenknecht LE, D'Agostino R Jr, Savage PJ, O'Leary DH, Saad MF, Haffner SM. Duration of diabetes and carotid wall thickness. The Insulin Resistance Atherosclerosis Study (IRAS). Stroke 1997; 28: 999-1005.
- Ciccone M, Maiorano A, De Pergola G, Minenna A, Giorgino R, Rizzon P. Microcirculatory damage of common carotid artery wall in obese and non-obese subjects. Clin Hemorheol Microcirc 1999; 21: 365-74.
- Klein R, Sharrett AR, Klein BE, Moss SE, Folsom AR, Wong TY, et al. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the atherosclerosis risk in communities study. Ophthalmology. 2002; 109:1225–34.
- Salonen R, Salonen JT. Determinants of carotid intima-media thickness: a population-based ultrasonography study in eastern Finnish men. J Intern Med 1991; 229: 225-31.
- Geroulakos G, Ramaswami G, Veller MG, Fisher GM, Renton S, Nicolaides A, et al. Arterial wall changes in type 2 diabetic subjects. Diabet Med 1994; 11: 692-5.
- Kanters SD, Algra A, Banga JD. Carotid intima-media thickness in hyperlipidemic type I and type II diabetic patients. Diabetes Care 1997; 20: 276-80.
- 23. Naya T, Hosomi N, Ohyama H, Ichihara S, Ban CR, Takahashi T. Smoking, fasting serum insulin, and obesity are the predictors of carotid atherosclerosis in relatively young subjects. Angiology 2007; 58: 677-84.